Amgen, Inc.’s products in highly competitive spaces, such as rheumatoid arthritis and migraine, experienced sales volume declines in the fourth quarter, contributing to a Q4 revenue total that fell below analyst expectations. The commercial performance announced on 7 February highlights the company’s need for near-term growth drivers beyond its two new launches, Lumakras (sotorasib) and Tezspire (tezepelumab), on the eve of a business review of Amgen’s long-term growth plans.
The company did not host a same-day call to go over its Q4 and full-year 2021 financial performance with analysts and investors, but will hold a four-hour call on 8 February to discuss commercial strategy for approved products, outline Amgen’s
